Vyvanse regulatory update

FDA approved Vyvanse lisdexamfetamine dimesylate for the maintenance treatment of ADHD in adults. Vyvanse is already marketed in the U.S. to treat ADHD in patients aged >=6 years. The prodrug of amphe...